You are here: Home » PTI Stories » National » News
Business Standard

Sundyota Numandis launches anti-diarrhea probiotic

Business Finance

Press Trust of India  |  Ahmedabad 

City-based healthcare solutions firm Sundyota Numandis today announced the pan-India launch of its anti-diarrhea probiotic product Lactobacillus rhamnosus GG, considered as the world's most scientifically studied probiotic for gastro-intestinal health.

To make this product available in India, Sundyota Numandis has entered into a strategic partnership with Italian firm Probiotical, a global leader in bacterial probiotic therapies, announced Dinesh Arora, managing director and chief executive officer of Sundyota Numandis Group, at a press meet here today.

"As per the agreement, Sundyota Numandis procures coated oro-soluble L.rhamnosus GG formula from the Italian firm and undertakes its manufacturing for the Indian market under the brand name SuperFlora GG. It will be sold in a sachet form," said Arora.

Probiotics are live bacteria and yeasts which are considered good for health, especially the digestive system. Unlike anti-biotic drugs, probiotics does not leave any harmful side effects in the body, he added.

Apart from selling their product, the company has also entered into a strategic alliance with Cipla for marketing the same product under the brand name Unobiotics.

"Such agreement is aimed at extending benefits to a larger consumer base," said Arora.

In his opinion, the Indian probiotic market is valued at about Rs 1,000 crore and growing at a rate of 15 per cent.

"While probiotics are very popular in western countries, it is now becoming popular in India. We estimate that the market would touch the Rs 10,000-crore mark in the next 10 years" he said.

While the current product is being manufactured by a third party at its facility in Himachal Pradesh, Arora said Sundyota Numandis plans to start its own manufacturing facility at Changodar industrial area here in near future with an investment of Rs 51 crore.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, April 11 2018. 16:40 IST